Patents by Inventor Alan Lau

Alan Lau has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12378295
    Abstract: Novel compositions and methods relating to or derived from a rationally designed fusion protein composition combines a therapeutic antibody with an IL2 mutant that can simultaneously enhance anti-tumor immunity or derepress tumor-associated immunosuppression along with direct activation of effector cells by IL2 without activating Treg are provided. The fusion protein can be used to prevent or therapeutically treat cancer.
    Type: Grant
    Filed: October 29, 2019
    Date of Patent: August 5, 2025
    Assignees: 1GLOBE BIOMEDICAL CO., LTD., 1GLOBE HEALTH INSTITUTE LLC
    Inventors: Chiang J. Li, Shyam Unniraman, Hannah Bader, Alan Lau
  • Publication number: 20210388049
    Abstract: Novel compositions and methods relating to or derived from a rationally designed fusion protein composition combines a therapeutic antibody with an IL2 mutant that can simultaneously enhance anti-tumor immunity or derepress tumor-associated immunosuppression along with direct activation of effector cells by IL2 without activating Treg are provided. The fusion protein can be used to prevent or therapeutically treat cancer.
    Type: Application
    Filed: October 29, 2019
    Publication date: December 16, 2021
    Inventors: Chiang J. Li, Shyam Unniraman, Hannah Bader, Alan Lau
  • Patent number: 9967248
    Abstract: Described are techniques for establishing secure communication channels between user devices and service providing devices. Correspondence between a request received from a user device and security data may be used to determine that the user device has provided a valid access credential. The access credential may be replaced with a subsequent access credential after use. Correspondence between the request and service data may be used to determine that the request may be processed by the receiving service and that the user device has the permissions necessary for the request to be processed. Portions of the request that meet these criteria may be provided to the service. The secure communication channel may also be used to provide the response from the service to the user device.
    Type: Grant
    Filed: December 28, 2015
    Date of Patent: May 8, 2018
    Assignee: Amazon Technologies Inc.
    Inventors: Yu-Hsiang Cheng, Siddhartha Shankara Rao, Robert Dale Francis, Da Chen, Ruoyu Fei, Jingyu Ji, Christopher Chad Lake, Alan Lau, Hanyu Liu, Ajaykumar Selvaraj, Haifeng Xu
  • Publication number: 20060155418
    Abstract: Direct slicing of CAD models to generate process planning instructions for solid freeform fabrication may overcome inherent disadvantages of using STL format in terms of the process accuracy, ease of file management, and incorporation of multiple materials. This paper will present the results of our development of a direct slicing algorithm for layered freeform fabrication. The direct slicing algorithm was based on a neutral, international standard (ISO 10303) STEP-formatted NURBS geometric representation and is intended to be independent of any commercial CAD software. The following aspects of the development effort will be presented: 1) Determination of optimal build direction based upon STEP-based NURBS models; 2) Adaptive subdivision of NURBS data for geometric refinement; and 3) Ray-casting slice generation into sets of raster patterns.
    Type: Application
    Filed: April 12, 2004
    Publication date: July 13, 2006
    Applicant: Therics, Inc.
    Inventors: Thomas Bradbury, Binil Starly, Wing Lau, Wei Sun, Alan Lau, Adolphe Youssef, Christopher Gaylo
  • Publication number: 20040197913
    Abstract: Retroviral integration is promoted in mammalian cells by inhibition of RAD52 DNA-binding activity, e.g. using RNAi. This is useful in gene therapy, especially ex vivo. Retroviral integration is inhibited by increasing mammalian RAD52 DNA-binding activity, useful in inhibiting retroviruses.
    Type: Application
    Filed: September 8, 2003
    Publication date: October 7, 2004
    Inventors: Mark James O'Connor, Stephen Philip Jackson, Alan Lau
  • Publication number: 20040014701
    Abstract: Ataxia telangiectasia mutated (ATM)-dependent DNA damage signalling mechanisms are involved in retroviral and retrotransposon integration. Screening methods for inhibitors of retroviral and retrotranspons activity comprise inhibiting the ATM-dependent DNA damage signalling pathway, e.g. by disrupting interaction between components of the pathway. Inhibitors are useful as anti-retroviral agents, e.g. in inhibition of HIV.
    Type: Application
    Filed: July 18, 2003
    Publication date: January 22, 2004
    Inventors: Mark James O'Connor, Stephen Philip Jackson, Alan Lau